Apart from some minor frustrations with revenue recognition due to delays in trial recruitment, I really like the report fundamentals. 1Q22 was a massive outlier quarter so was always going to make 1Q23 numbers look ordinary on a YOY basis. However, the reality is that 1Q23 was the third biggest quarter ever for new clinical trials contracts signed and subsequently we now have a record $148.3M revenue backlog. And despite revenue recognition delays and payout of staff annual bonuses this quarter, the company was still cash flow positive.
Throw on top of that the Lecanemab results tailwind and the long term thesis is well and truly intact.
- Forums
- ASX - By Stock
- CGS
- Ann: Business Update and September 2022 Quarter Cashflow
Ann: Business Update and September 2022 Quarter Cashflow, page-5
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGS (ASX) to my watchlist
(20min delay)
|
|||||
Last
91.0¢ |
Change
0.010(1.11%) |
Mkt cap ! $157.1M |
Open | High | Low | Value | Volume |
90.0¢ | 91.0¢ | 89.0¢ | $34.07K | 38.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 88.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.0¢ | 1151 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1143 | 0.875 |
1 | 3000 | 0.870 |
1 | 3000 | 0.860 |
3 | 2400 | 0.850 |
1 | 1200 | 0.830 |
Price($) | Vol. | No. |
---|---|---|
0.920 | 1151 | 1 |
0.940 | 4760 | 1 |
0.945 | 6600 | 1 |
0.950 | 10122 | 1 |
0.970 | 25000 | 1 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |